Saturday morning well spent listening to Dustin Boothe discuss the future of #radioligand therapy- inspiring and informative! Intermountain Health IntermountainMedCtr

Update #radioligand #cancer #oncology #targetedtherapy #precisionmedicine Sanofi, RadioMedix, and Orano Med Partner on Next-Generation Radioligand Therapy for Rare Cancers (nextedge.in)

.Novartis expands #radioligand therapy facilities | #oncology #radiotherapy #theranostics buff.ly/47pcM2f

.Novartis has begun construction of two new #radioligand therapy (#RLT) manufacturing facilities in the US. ➡️ Read more about the facilities, one of which will be #Novartis’ first in-house production facility for isotopes:buff.ly/4dUtsRU #Radioligands

With 1 in 44 men losing their lives each year to #ProstateCancer, ARTBIO highlights the urgent need for regular screenings and innovative therapies during #ProstateCancerAwarenessMonth. We are redefining patient-centric cancer care with #alpha #radioligand #therapy. #ART #RLT

Dr. Elisa Napoli, Ph.D., joins ARTBIO as Associate Director of Nuclear Physics, Radiopharmaceuticals, and Metrology! Her expertise in radiopharmaceuticals and radionuclide standardization will be vital in advancing our #alpha #radioligand #therapy platform. Welcome!

Dr. Sanjay Sharma, MSc, CRadPhr, PhD, joins ARTBIO as our new VP of CMC! With 15+ years in radiopharmaceuticals, his deep expertise in operations and regulatory processes will drive our #alpha #radioligand therapy platform forward. Excited for the innovations ahead! #team #RLT

Love how down to earth Novartis CEO Vas Narasimhan is in explaining #radioligand therapies - what a great origin story! youtube.com/watch?v=FV-THx…

The Next Generation of Cancer Treatment! By sequentially administering the targeting molecule and #radioligand, #pretargeting harnesses antibodies to target #tumors effectively while minimizing side effects and reducing #radioactivity in healthy tissues. perspectivetherapeutics.com/newsroom/press…

Lisa Wells, PhD reviews study design for the development of a PET radioligand for a novel target in CNS models. Discover the importance of target expression and candidate ligand characteristics prior to in vivo imaging bit.ly/4cJEzMp #PET #radioligand

Discover our #NanobodyBioconjugation Service! Expand your #Research & #Therapeutic applications with diverse #Conjugates like #Fluorophores, #HRP, #Biotin, #EV, #Drug, and #Radioligand. Tailored solutions for your needs. Learn more at jotbody.com. #LifeScience

⭐Research highlight: The #NETTER2 trial establishes #radioligand therapy as a new first-line treatment for patients with high-grade, advanced gastroenteropancreatic neuroendocrine tumors — for whom evidence-based treatments are lacking. The Lancet nature.com/articles/d4159…

Great review by Nature Biotechnology on the #radiopharmaceutical industry, just after the SNMMI Annual Meeting. ARTBIO's pioneering #Pb212-based #alpha #radioligand #therapies are gaining traction, in light of supply and purity challenges with Actinium-225. nature.com/articles/s4158…

📊 Research presented at #SNMMI24 found that #radioligand therapy with [177Lu]Lu-PSMA I&T shows promising safety and efficacy results in elderly patients with #ProstateCancer. 📰 Read More: buff.ly/3RIEaSh

We believe #Radioligand therapy (RLT) has the potential to transform cancer care. We’re proud that our study investigating RLT has been selected as Abstract of the Year by SNMMI, reinforcing its potential for patients in need. #ReimagineMedicine #SNMMI24

#UKIO #UKIO24 #Radioligand #Wellbeing #Oncology #Imaging #WeAreInHealth

Neue Hoffnung für Patienten mit besonders tückischen Krebsarten: Mit neuen Radiopharmaka will Trimt Radeberg die Diaganose und Behandlung der Krebszellen verbessern oiger.de/2024/05/27/str… #Krebs #Tumor #Metastase #Radioligand #Pakreas #Gehirn

On this day last month, we kicked off a great #SwissBiotechDay, where we connected with biotech leaders, investors & future partners. Highlights were several panel discussions & presentations on Life Science Cares Switzerland, investors, #radioligand therapies & MP’s progress.

Amazing talk from Oliver Sartor Mayo Clinic - a wonderful overview of multiple practice-changing trials (& forthcoming studies!) related to #radioligand tx & #novelimaging in #prostatecancer! We will have to have you back in person soon! Tanya Dorff Alex Chehrazi-Raffle, MD Abhishek Tripathi

Lisa Wells, PhD reviews study design for the development of a PET radioligand for a novel target in CNS models. Discover the importance of target expression and candidate ligand characteristics prior to in vivo imaging bit.ly/4buGcgp #PET #radioligand